AAXT Stock Overview
Aamaxan Transport Group, Inc. manufactures medical products that are used during hemodialysis therapy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Aamaxan Transport Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | -99.92% |
| 5 Year Change | -99.96% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| AAXT | US Transportation | US Market | |
|---|---|---|---|
| 7D | 0% | -4.9% | -3.7% |
| 1Y | n/a | 30.8% | 20.5% |
Return vs Industry: Insufficient data to determine how AAXT performed against the US Transportation industry.
Return vs Market: Insufficient data to determine how AAXT performed against the US Market.
Price Volatility
| AAXT volatility | |
|---|---|
| AAXT Average Weekly Movement | n/a |
| Transportation Industry Average Movement | 5.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AAXT has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AAXT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Chen Zhong | n/a |
Aamaxan Transport Group, Inc. manufactures medical products that are used during hemodialysis therapy. The company was founded as Shanghai Medical Technology Co., Ltd. and changed its name to Aamaxan Transport Group, Inc. in April 2008.
Aamaxan Transport Group, Inc. Fundamentals Summary
| AAXT fundamental statistics | |
|---|---|
| Market cap | US$1.60k |
| Earnings (TTM) | US$7.39m |
| Revenue (TTM) | US$39.13m |
0.0x
P/E Ratio0.0x
P/S RatioIs AAXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAXT income statement (TTM) | |
|---|---|
| Revenue | US$39.13m |
| Cost of Revenue | US$24.46m |
| Gross Profit | US$14.67m |
| Other Expenses | US$7.28m |
| Earnings | US$7.39m |
Last Reported Earnings
Jun 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did AAXT perform over the long term?
See historical performance and comparison